Gadoteridol

Summary

Gadoteridol (CHEMBL1200593) is an approved small molecule (ATC V08CA04); indicated across 7 conditions including central nervous system disorder and glioblastoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08CA04
• Indications: 7 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200593
Name	Gadoteridol
Type	Small molecule
Max phase	4
ATC	V08CA04

Also known as: Gadoteridol, NSC-760055, Prohance, Prohance multipack, SQ 32,692, SQ-32692, GADOTERIDOL, gadoteridol, SID144206576, SID144206679, SID170466854

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
central nervous system disorder	3	MONDO:0002602	EFO:0009386
glioblastoma	1	MONDO:0018177	EFO:0000519
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499
paraganglioma	1	MONDO:0000448	EFO:1000453
glioma	1	MONDO:0021042	MONDO:0100342
chronic progressive multiple sclerosis	0	MONDO:0005284	EFO:0003840
secondary progressive multiple sclerosis	0	MONDO:0000450	EFO:0008522

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	4
Not specified	4
PHASE4	2
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04373564	PHASE4	RECRUITING	Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT01613417	PHASE4	COMPLETED	Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
NCT00522951	PHASE3	COMPLETED	SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
NCT00709852	PHASE3	COMPLETED	Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
NCT05915702	PHASE3	COMPLETED	A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
NCT05915728	PHASE3	COMPLETED	A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
NCT04608812	PHASE1	TERMINATED	Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
NCT05357833	EARLY_PHASE1	COMPLETED	Novel Imaging Markers in SPMS
NCT02359097	Not specified	COMPLETED	Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
NCT02481882	Not specified	UNKNOWN	Baseline Cortical Haemodynamics in MS
NCT03396822	Not specified	COMPLETED	Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
NCT03750188	Not specified	COMPLETED	Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).